X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (861) 861
Newspaper Article (75) 75
Book Chapter (19) 19
Publication (4) 4
Patent (3) 3
Conference Proceeding (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (320) 320
life sciences & biomedicine (294) 294
humans (259) 259
heart failure (254) 254
cardiovascular system & cardiology (240) 240
cardiac & cardiovascular systems (239) 239
male (209) 209
female (192) 192
middle aged (148) 148
aged (147) 147
analysis (113) 113
prognosis (109) 109
abridged index medicus (100) 100
heart failure - physiopathology (95) 95
heart failure - drug therapy (94) 94
mortality (85) 85
heart failure - mortality (75) 75
treatment outcome (72) 72
risk factors (66) 66
cardiovascular (65) 65
research (55) 55
adult (54) 54
usage (51) 51
technical journals (49) 49
follow-up studies (48) 48
management journals (47) 47
care and treatment (46) 46
cardiac patients (43) 43
double-blind method (43) 43
heart failure - complications (42) 42
cardiology and cardiovascular medicine (38) 38
heart failure - blood (38) 38
peripheral vascular disease (38) 38
biomarkers - blood (37) 37
stroke volume - physiology (37) 37
heart failure - diagnosis (35) 35
time factors (35) 35
aged, 80 and over (34) 34
clinical trials (34) 34
prospective studies (34) 34
tetrazoles - therapeutic use (34) 34
echocardiography (33) 33
computing journals (32) 32
natriuretic peptides (32) 32
hospitalization (31) 31
biomarkers (30) 30
mathematical models (30) 30
algorithms (29) 29
heart (28) 28
valsartan (28) 28
blood pressure (27) 27
patients (27) 27
quality of life (27) 27
spironolactone (27) 27
stroke volume (27) 27
drug therapy (26) 26
heart failure - therapy (26) 26
heart failure with preserved ejection fraction (26) 26
methods (26) 26
patient outcomes (26) 26
angiotensin ii type 1 receptor blockers - therapeutic use (25) 25
chronic disease (25) 25
materials and manufacturing (25) 25
cardiology (24) 24
heart diseases (24) 24
management (24) 24
natriuretic peptide, brain - blood (24) 24
studies (24) 24
cardiac output (23) 23
hospitalization - statistics & numerical data (23) 23
predictive value of tests (23) 23
proportional hazards models (23) 23
cardiac and cardiovascular systems (22) 22
kardiologi (22) 22
technology (22) 22
anemia (21) 21
computing science, applications and software (21) 21
diagnosis (21) 21
healthcare and leisure journals (21) 21
morbidity (21) 21
retrospective studies (21) 21
valine - analogs & derivatives (21) 21
heart attacks (20) 20
mineralocorticoid receptor antagonists - therapeutic use (20) 20
ejection fraction (19) 19
valine - therapeutic use (19) 19
classification (18) 18
electrocardiography (18) 18
india (18) 18
mathematical analysis (18) 18
peptide fragments - blood (18) 18
survival analysis (18) 18
survival rate (18) 18
animals (17) 17
business (17) 17
diabetes (17) 17
dosage and administration (17) 17
operational management, marketing and services (17) 17
optimization (17) 17
outcomes (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 10/2013, Volume 8, Issue 10, pp. 1800 - 1807
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2016, Volume 68, Issue 5, pp. 483 - 486
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 15, pp. 1383 - 1392
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 1995 - 2008
In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients... 
NEPRILYSIN INHIBITION | OUTCOMES | COTRANSPORTER 2 INHIBITORS | MECHANISM | EMPAGLIFLOZIN | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Ventricular Dysfunction, Left - complications | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Heart Failure - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kaplan-Meier Estimate | Stroke Volume - drug effects | Combined Modality Therapy | Hospitalization | Heart Failure - drug therapy | Cardiovascular Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Ventricular Dysfunction, Left - drug therapy | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Measurement | Heart failure | Dapagliflozin | Patient outcomes | Physiological aspects | Cardiac output | Drug therapy | Testing | Intravenous administration | Renal function | Clinical trials | Hypoglycemia | Evidence-based medicine | Clinical outcomes | Sodium | Hemoglobin | Patient safety | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Ejection fraction | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2019, Volume 381, Issue 17, pp. 1609 - 1620
Patients with heart failure with preserved ejection fraction were assigned to receive sacubitril–valsartan or valsartan. At a median of 35 months, there was no... 
MIDDLE CHILD | MIDRANGE | IMPAIRED SYSTOLIC FUNCTION | SPIRONOLACTONE | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Valsartan - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Tetrazoles - administration & dosage | Cardiovascular Diseases - mortality | Female | Aminobutyrates - administration & dosage | Double-Blind Method | Valsartan - adverse effects | Hypotension - chemically induced | Heart Failure - drug therapy | Stroke Volume | Neprilysin - antagonists & inhibitors | Sex Factors | Quality of Life | Angioedema - chemically induced | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Heart failure | Treatment outcome | Care and treatment | Usage | Safety and security measures | Hospitals | Patient outcomes | Analysis | Angiotensin | Causes of | Statistics | Admission and discharge | Renal function | Cardiomyopathy | Mortality | Angioedema | Clinical trials | Hospitalization | Coronary artery disease | Hypotension | Heart rate | Hyperkalemia | Patient safety | Death | Neprilysin | Heart diseases | Pharmaceuticals | Ejection fraction | Index Medicus | Abridged Index Medicus
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 21, pp. 2606 - 2618
Abstract Background Recent clinical trials highlight the need for better models to identify patients at higher risk of sudden death. Objectives The authors... 
Cardiovascular | Internal Medicine | heart failure | implantable cardioverter-defibrillator | risk models | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Heart Failure - complications | Prognosis | Survival Rate - trends | Follow-Up Studies | Risk Assessment | Death, Sudden, Cardiac - epidemiology | Humans | Middle Aged | Risk Factors | Death, Sudden, Cardiac - prevention & control | Male | Death, Sudden, Cardiac - etiology | Incidence | Washington - epidemiology | Heart Failure - therapy | Propensity Score | Time Factors | Defibrillators, Implantable | Primary Prevention - methods | Female | Registries | Aged | Retrospective Studies | Heart Failure - mortality | Heart failure | Defibrillators | Implants, Artificial | Prosthesis | Risk assessment | Risk factors | Myocardial infarction | Heart | Therapy | Arrhythmia | Syngeneic grafts | Cardiomyopathy | Clinical trials | Risk | Criteria | Congestive heart failure | Mental depression | Security | Beta blockers | Prevention | Ethics | Reduction | Ischemia | Blood pressure | Mathematical models | Public health | Age | Creatinine | Metoprolol | Mortality | Heart transplantation | Health risks | Data processing | Survival | Morbidity | Studies | Survival analysis | Sodium | Angiotensin | Death | Infarction | Dialysis | Models | Ventricle | Cardiovascular diseases | Circulation | Kidney transplantation | Index Medicus | Abridged Index Medicus | prophylactic | metaanalysis | ejection fraction | death | survival | association | trial | Kardiologi | Cardiac and Cardiovascular Systems | implantation | primary prevention | mortality | cardiac-resynchronization therapy
Journal Article